When critical moments arise, INOmax Total Care is there to help support uninterrupted delivery of INOMAX. Watch the stories of a parent and practitioners who appreciate the support INOmax Total Care provides.

Learn more about the unmatched offering you receive to help ensure uninterrupted delivery of nitric oxide when you’re contracted with INOmax Total Care.

See which common underlying diseases can cause hypoxic respiratory failure (HRF).

INOMAX is an inhaled pulmonary vasodilator that selectively dilates the pulmonary vasculature and improves ventilation and perfusion (V/Q) mismatch.1 Learn how INOMAX can help stop the cascade of hypoxic respiratory failure (HRF) in term and near-term neonates diagnosed with pulmonary hypertension.

INOmax DSIR Plus Delivery Systems bring together innovative engineering with an intuitive user experience.1 See the complete array of patient safety features now.

Reference: 1. Data on file. Mallinckrodt Pharmaceuticals

Compare the different features of INOmax DSIR Plus Delivery Systems.

Review key safety features of the INOmax DSIR Plus Delivery Systems.

Learn more about the innovations that have kept the INOmax delivery systems constantly evolving to meet the ever-changing demands of the critical care space.

INOMAX customers receive 24/7/365 service, education, and technical support. See all the benefits that only come with an INOmax Total Care contract.

INOMAX cylinders, calibration gas, and delivery system consumables and accessories are delivered at no additional charge as part of your contract.

See the complete inventory of INOmax DSIR Plus Delivery System consumables now.

Your INOMAX Critical Care Business Manager and National Account Manager are available to help you navigate the reimbursement process.

Learn more about accessing INOMAX reimbursement support services here.

FLEXtraNet invoicing is designed to help make the invoicing process more transparent and easy. Learn more about the benefits of FLEXtraNet now.

Comprehensive clinician resources are available to you at no extra cost, from device training and technical bulletins to on-demand webinars. Access a variety of support materials and learn more about the resources included in your INOmax Total Care contract.

Access case studies and other supplemental resources on inhaled nitric oxide as treatment for HRF associated with pulmonary hypertension.

Hear highly respected clinicians discuss treatment of neonates with HRF associated with pulmonary hypertension in this INOMAX webinar. Images are used with permissions.

Many organizations are focused on reducing device-related errors and failures. Download information on the latest efforts to improve patient safety.

[00:00](Indication and Contraindication)
INOMAX® (nitric oxide) gas, for inhalation is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.

Please see full Important Safety Information at the end of this video, and visit INOMAX.com for Full Prescribing Information.

[00:42]Optimal oxygenation of the pulmonary vasculature is vital. In order for this to occur, ventilation and perfusion matching, or V/Q matching, is required.

[0:55]
Healthy neonates can achieve the ideal V/Q ratio of approximately 1.

[1:07]One cause of V/Q mismatching could be intrapulmonary shunting, which can cause the V/Q ratio to be less than 1.

[1:15]Another cause of V/Q mismatching could be the creation of dead space, where there is adequate ventilation but poor perfusion. This could cause the V/Q ratio to be greater than 1.

[1:28]Inhaled nitric oxide, or iNO, is an inhaled pulmonary vasodilator that can improve V/Q matching when there is pulmonary hypertension.

[1:36]How does iNO address V/Q mismatch?

[1:40]Inhaled nitric oxide is delivered with ventilatory support

[1:46]and with ventilatory support has a preferential affinity for well-recruited alveoli.

[1:50]
Once in the alveoli, inhaled nitric oxide diffuses into the smooth muscle of the arteriole.

[1:57]There, inhaled nitric oxide activates transduction pathways,

[2:00]relaxing the smooth muscle cells,

[2:07]which results in selective and local vasodilation of the pulmonary vasculature

[2:12]
and, in turn, improves V/Q matching.

[2:19](Logo appears)
INOMAX® (nitric oxide) gas, for inhalation, also known as inhaled nitric oxide, is an FDA-approved drug that selectively dilates the pulmonary vasculature.

[2:31]INOMAX is rapidly inactivated by hemoglobin. Because it is inhaled, INOMAX minimizes systemic vasodilation. Nitrate, the predominant metabolite of nitric oxide, is rapidly cleared by the kidneys.

[2:46]INOMAX can help restore VQ matching in your vulnerable patients. When you have a neonate patient who suffers from V/Q mismatching due to hypoxic respiratory failure associated with pulmonary hypertension, think INOMAX, because every moment counts.

[3:03]Important Safety Information

INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.

Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation.

Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.

Monitor for PaO2, inspired NO2, and methemoglobin during INOMAX administration.

INOMAX must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

INOMAX is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INOMAX® IMPORTANT SAFETY INFORMATION

INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.

Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation.

Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.

Monitor for PaO2, inspired NO2, and methemoglobin during INOMAX administration.

INOMAX must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

INOMAX is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INOMAX® IMPORTANT SAFETY INFORMATION

INOMAX is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.

Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation.

Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.

Monitor for PaO2, inspired NO2, and methemoglobin during INOMAX administration.

INOMAX must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective
owners.

This website may identify third party organizations and provide links to third party websites or other third party information (third party content). The third party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician's medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

By viewing this site you agree to our
Terms of Use. The product
information provided in this site is intended only for residents of the United States.The
product discussed herein may have different product labeling in different countries.